Brokerage firm Cantor Fitzgerald Downgrades its rating on Tobira Therapeutics Inc(NASDAQ:TBRA). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by Cantor Fitzgerald was issued on Sep 21, 2016.
In a different note, Cantor Fitzgerald said it Initiates Coverage on Tobira Therapeutics Inc, according to a research note issued on Jul 6, 2016. The shares have been rated ‘Buy’ by the firm.
Tobira Therapeutics Inc (TBRA) made into the market gainers list on Tuesdays trading session with the shares advancing 720.89% or 34.17 points. Due to strong positive momentum, the stock ended at $38.91, which is also near the day’s high of $41.39. The stock began the session at $33 and the volume stood at 1,27,64,728 shares. The 52-week high of the shares is $41.39 and the 52 week low is $3.76. The company has a current market capitalization of $732 M and it has 1,88,21,231 shares in outstanding.
Tobira Therapeutics Inc(TBRA) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.06M. Analysts had an estimated revenue of $50.00K. Earnings per share were $-0.71. Analysts had estimated an EPS of $-0.63.
Several Insider Transactions has been reported to the SEC. On Jul 13, 2016, A/s Novo (10% owner) sold 59,067 shares at $12.06 per share price.
Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Companys lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.